Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 08/12/2025 GMT			5-day change	1st Jan Change
121.19 ^USD	-0.02%		-2.53%	+31.20%

12-08	Gilead Sciences' Kite Says Yescarta Shows 'Consistent' Benefits in Large B-cell Lymphoma	MT
12-08	Gilead Unit Reports Encouraging Phase 1 Data Showing High Response Rates for Bicistronic CAR T-Cell Candidates in B-Cell Lymphoma	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

2.AJbzfSmx7pltY4RzHk_0W-5bkjmIg9cvPy9siGpchAc.MdvDDEfcgP0rIOwdSD7BLrRu92r_9Id7YEUvxDo720Zz1KwfYNzf_zQixQ~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

11-21	Mizuho Adjusts Price Target on Gilead Sciences to $140 From $131, Maintains Outperform Rating	MT
11-13	Needham Adjusts Gilead Sciences Price Target to $140 From $133, Maintains Buy Rating	MT
11-13	Daiwa Securities Adjusts Gilead Sciences Price Target to $129 From $128, Maintains Outperform Rating	MT
11-13	Scotiabank Initiates Gilead Sciences at Sector Outperform With $140 Price Target	MT
11-10	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $153 From $143	MT
11-07	Gilead provides update on phase 3 ASCENT-07 study	RE
11-04	Argus Research Adjusts Gilead Sciences Price Target to $135 From $130, Maintains Buy Rating	MT
10-31	Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating	MT
10-31	Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating	MT
10-31	Wells Fargo Adjusts Price Target on Gilead Sciences to $145 From $140, Maintains Overweight Rating	MT
10-31	JPMorgan Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating	MT
10-31	RBC Capital Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Sector Perform Rating	MT
10-23	Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating	MT
10-23	TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating	MT
10-20	BMO Capital Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Outperform Rating	MT
10-17	Goldman Sachs Raises Gilead Sciences Price Target to $108 From $105, Neutral Rating Maintained	MT
10-13	Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025	CI
10-10	Assembly Biosciences, Inc. Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections Europe	CI
10-09	Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating	MT
10-08	Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating	MT
10-08	RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating	MT
09-16	JPMorgan Adjusts Price Target on Gilead Sciences to $145 From $135, Maintains Overweight Rating	MT
09-12	Rothschild & Co Redburn Adjusts Gilead Sciences Price Target to $143 From $136, Maintains Buy Rating	MT
08-20	Bernstein Adjusts Price Target on Gilead Sciences to $135 From $120, Maintains Outperform Rating	MT
08-19	Daiwa Upgrades Gilead Sciences to Outperform From Neutral, Adjusts Price Target to $128 From $104	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					+7.79%
	ELI LILLY AND COMPANY					+6.65%
	JOHNSON & JOHNSON					+0.89%
	ABBVIE INC.					+9.16%
	ROCHE HOLDING AG					+0.24%
	ASTRAZENECA PLC					+9.84%
	NOVARTIS AG					+1.2%
	MERCK & CO., INC.					+7.77%
	NOVO NORDISK A/S					+30.7%
	AMGEN INC.					+0.94%
	Average					+7.52%
	Weighted average by Cap.					+6.64%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

121.19USD

Average target price

130.63USD

Spread / Average Target

+7.79%

High Price Target

153.00USD

Spread / Highest target

+26.25%

Low Price Target

105.00USD

Spread / Lowest Target

-13.36%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Needham & Co.
Daiwa Securities
Scotiabank
Rothschild & Co Redburn
Argus
Wells Fargo Securities
RBC Capital Markets
JPMorgan Chase
Morgan Stanley
Goldman Sachs
Wolfe Research
TD Cowen
BMO Capital
Cantor Fitzgerald
Citigroup
Bernstein
Deutsche Bank Securities
Oppenheimer
Truist Securities
UBS
Baird
HSBC
DBS Bank
Leerink Partners
BofA Securities
Jefferies & Co.
Redburn Atlantic
Piper Sandler
Maxim
Raymond James
Barclays
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Redburn
DZ BANK	Elmar Kraus